Patents by Inventor Jay A. Berzofsky

Jay A. Berzofsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190242887
    Abstract: A molecular nanotag is disclosed that includes a core nanoparticle with a diameter of less than about 100 nm, with an optional shell surrounding the core, and an armor bound to the surface of the core nanoparticle, or if present, to the surface of the shell. The molecular nanotag also includes a functionalized end with a fixed number of binding sites that can selectively bind to a molecular targeting ligand. Any one of, or any combination of, the core, the shell and the armor contribute to fluorescence, light scattering and/or ligand binding properties of the molecular tag that are detectable by microscopy or in a devices that measures intensity or power of fluorescence and light scattering.
    Type: Application
    Filed: October 23, 2017
    Publication date: August 8, 2019
    Applicant: The United States of America, as represented by the Secretary, Dept of Health & Human Services
    Inventors: Jennifer C. Jones, Aizea Morales-Kastresana, Jay A. Berzofsky, Joshua Welsh, Ari Rosner
  • Patent number: 10286050
    Abstract: Immunogenic T cell receptor ? alternate reading frame protein (TARP) peptide compositions that include multiple epitopes of the TARP protein are described. The disclosed compositions can be used for the treatment of TARP-expressing cancers, such as prostate cancer, breast cancer and mesothelioma. In some embodiments, the TARP peptide compositions disclosed herein include sets of overlapping TARP peptides that each have a length of about 15 to about 25 amino acids, and comprise about 5 to about 15 amino acids that are identical to at least another overlapping peptide in the set. In particular examples, the combination of the overlapping TARP peptides in the set encompasses the complete amino acid sequence of human TARP. The multi-epitope peptide compositions described herein include both CD4 and CD8 epitopes, a feature that is important for eliciting CD4+ T cell and CD8+ T cell, as well as humoral, immune responses.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: May 14, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Lauren V. Wood, Jay A. Berzofsky, Brenda D. Roberson, Masaki Terabe
  • Publication number: 20180344828
    Abstract: Recombinant adenoviruses expressing the extracellular (EC) and transmembrane (TM) domains of human HER2 (HER2ECTM) are described. The recombinant adenoviruses express a chimeric fiber protein having the adenovirus type 35 (Ad5) shaft and knob domains, which facilitates transduction of human dendritic cells by the recombinant HER2ECTM expressing adenovirus. Compositions that include dendritic cells transduced by the recombinant adenovirus and their use for treating HER-positive tumors is described.
    Type: Application
    Filed: October 31, 2016
    Publication date: December 6, 2018
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, Baylor College of Medicine
    Inventors: Lauren V. Wood, Brenda D. Roberson, Jay A. Berzofsky, John C. Morris, Jason C. Steel, Masaki Terabe, Malcolm K. Brenner
  • Publication number: 20180064765
    Abstract: The present invention is directed to compositions comprising an immune checkpoint inhibitor or a T cell stimulator or a combination thereof, and a live attenuated recombinant Listeria strain comprising a fusion polypeptide comprising a truncated Listeriolysin O protein, a truncated ActA protein, or a PEST amino acid sequence fused to a tumor-associated antigen. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor or a cancer, comprising the step of administering the same.
    Type: Application
    Filed: July 17, 2015
    Publication date: March 8, 2018
    Inventors: Robert PETIT, Anu Wallecha, Samir Khleif, Zhisong Chen, Jay A. Berzofsky
  • Publication number: 20170165359
    Abstract: The present invention provides immunostimulatory combinations of TLR ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions.
    Type: Application
    Filed: August 23, 2016
    Publication date: June 15, 2017
    Inventors: Jay A. Berzofsky, Qing Zhu, Igor Belyakov
  • Publication number: 20170080064
    Abstract: The present invention is directed to methods for increasing T-cell effector cell to regulatory T cell ratio. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and tumor-associated antigen.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 23, 2017
    Inventors: Robert Petit, Anu Wallecha, Zhisong Chen, Jay A Berzofsky, Samir Khleif
  • Patent number: 9517243
    Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: December 13, 2016
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The University of Birmingham of Edgbaston
    Inventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
  • Publication number: 20160310585
    Abstract: Immunogenic T cell receptor ? alternate reading frame protein (TARP) peptide compositions that include multiple epitopes of the TARP protein are described. The disclosed compositions can be used for the treatment of TARP-expressing cancers, such as prostate cancer, breast cancer and mesothelioma. In some embodiments, the TARP peptide compositions disclosed herein include sets of overlapping TARP peptides that each have a length of about 15 to about 25 amino acids, and comprise about 5 to about 15 amino acids that are identical to at least another overlapping peptide in the set. In particular examples, the combination of the overlapping TARP peptides in the set encompasses the complete amino acid sequence of human TARP. The multi-epitope peptide compositions described herein include both CD4 and CD8 epitopes, a feature that is important for eliciting CD4+ T cell and CD8+ T cell, as well as humoral, immune responses.
    Type: Application
    Filed: December 12, 2014
    Publication date: October 27, 2016
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Lauren V. Wood, Jay A. Berzofsky, Brenda D. Roberson, Masaki Terabe
  • Patent number: 9474793
    Abstract: The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: October 25, 2016
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Andrew Catanzaro, Robert Yarchoan, Jay A. Berzofsky, Takahiro Okazaki, James T. Snyder, II, Samuel Broder
  • Patent number: 9421254
    Abstract: The present invention provides immunostimulatory combinations of TLR ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: August 23, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Qing Zhu, Igor Belyakov
  • Patent number: 9394352
    Abstract: POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: July 19, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Yi-Hsiang Huang, Masaki Terabe, Ira H. Pastan
  • Publication number: 20160101123
    Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.
    Type: Application
    Filed: October 9, 2015
    Publication date: April 14, 2016
    Inventors: Jay A . Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
  • Patent number: 9206245
    Abstract: Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor cell, methods of stimulating CD4+ and CD8+ T cells, and methods of treating or preventing cancer are further provided herein.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: December 8, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Leon T. van den Broeke, Crystal L. Mackall, Lee J. Helman
  • Patent number: 9168291
    Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: October 27, 2015
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The University of Birmingham
    Inventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
  • Publication number: 20150203830
    Abstract: The present invention provides peptides and proteins for use in second generation HIV vaccines and as diagnostic tools in the treatment and control of HIV infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an HLA epitope-enhanced vaccine. These findings define a critical balance between MHC affinity and receptor crossreactivity required for effective epitope enhancement and also demonstrate construction and efficacy of such a component of a new generation vaccine.
    Type: Application
    Filed: November 3, 2014
    Publication date: July 23, 2015
    Inventors: Jay A. BERZOFSKY, Takahiro OKAZAKI
  • Publication number: 20150010590
    Abstract: POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.
    Type: Application
    Filed: September 25, 2014
    Publication date: January 8, 2015
    Inventors: Jay A. Berzofsky, Yi-Hsiang Huang, Masaki Terabe, Ira H. Pastan
  • Publication number: 20140377306
    Abstract: The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus vector, such as a vaccinia virus vector, which comprises a nucleic acid sequence encoding IL-15.
    Type: Application
    Filed: January 15, 2014
    Publication date: December 25, 2014
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health & Human Services
    Inventors: Liyanage P. Perera, Thomas A. Waldmann, Sang-Kon Oh, Jay A. Berzofsky
  • Publication number: 20140348786
    Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.
    Type: Application
    Filed: August 7, 2014
    Publication date: November 27, 2014
    Inventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
  • Patent number: 8877914
    Abstract: The present invention provides compositions comprising a vector including a nucleic acid comprising a nucleotide sequence encoding a peptide having the sequence X1LYQYMDDV, wherein X1 is any hydrophobic amino acid. The compositions are used to induce an immune response against human immunodeficiency virus (HIV).
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: November 4, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Takahiro Okazaki
  • Patent number: 8871902
    Abstract: POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: October 28, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Yi-Hsiang Huang, Masaki Terabe, Ira H. Pastan